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Summary
Background and aims: Cardiovascular disease is the most common cause of morbidity 
and	mortality	among	people	with	type	2	diabetes	mellitus	(T2DM).	The	main	contribu-
tors	to	cardiovascular	risk	in	T2DM	are	chronic	hyperglycaemia,	reduced	insulin	sensi-
tivity, hypertension and dyslipidaemia. Other cardiovascular risk factors include 
obesity and visceral adiposity, increased arterial stiffness and renal dysfunction. 
Results from clinical trials, including a long- term cardiovascular outcome study, have 
shown	that	sodium	glucose	co-	transporter	2	(SGLT2)	inhibitors	can	provide	multiple	
cardiometabolic benefits beyond glycaemic control including inducing mild osmotic 
diuresis, natriuresis and weight loss. This review article describes the effects of cana-
gliflozin on cardiovascular risk factors based on results from its clinical development 
programme.
Methods: This review is based on structured searches to identify literature related to 
the	effects	of	canagliflozin	on	cardiovascular	risk	factors	in	patients	with	T2DM.
Discussion and conclusions: Canagliflozin treatment has been shown to provide gly-
caemic improvements as well as reductions in blood pressure and body weight across 
a	broad	range	of	patients	with	T2DM,	 including	those	with	elevated	cardiovascular	
risk. Other observed effects of canagliflozin that may contribute to improved cardio-
metabolic outcomes include reduction in uric acid levels, decreased albuminuria and 
increases in serum magnesium. Results of ongoing long- term cardiovascular outcomes 
studies of canagliflozin are expected to provide additional evidence on the cardio-
metabolic effects of canagliflozin treatment.
1  | INTRODUCTION
Diabetes is a major global health emergency, affecting approximately 
415 million adults and contributing to five million deaths each year. 
It has been estimated that up to 91% of people with diabetes have 
type	2	diabetes	mellitus	 (T2DM).1	Cardiovascular	disease	 (CVD)	 is	a	
serious	complication	of	T2DM,	contributing	to	 the	majority	of	mor-
bidity and mortality in this population.2-4 Chronic hyperglycaemia and 
reduced insulin sensitivity, along with comorbidities of hypertension 
and dyslipidaemia, are the main contributors to an increased risk of 
CVD	in	people	with	T2DM.	Other	contributors	to	this	risk	may	include	
obesity, especially visceral adiposity, increased arterial stiffness and 
renal dysfunction.5
Recent findings from long- term, large- scale, cardiovascular out-
come	 trials	 of	 antihyperglycaemic	 agents	 (AHAs)	 have	 shown	 that	
some	 T2DM	 treatments	 can	 provide	 cardiometabolic	 benefits	 be-
yond	glycaemic	control.	For	example,	 in	 the	EMPA-	REG	OUTCOME	
trial	in	patients	with	T2DM	and	established	CVD,	the	sodium	glucose	
co-	transporter	2	(SGLT2)	 inhibitor	empagliflozin	was	associated	with	
a significant decrease in the risk of major cardiovascular events (three- 
point	 MACE;	 cardiovascular	 death,	 non-	fatal	 myocardial	 infarction	
[MI]	 and	 non-fatal	 stroke)	 vs	 placebo.6 Reduction in cardiovascular 
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death	drove	the	primary	finding,	as	the	rates	of	non-	fatal	MI	and	non-	
fatal stroke were not significantly different for empagliflozin and pla-
cebo.6 In addition, the risk of heart failure hospitalisation and all- cause 
mortality was significantly reduced with empagliflozin vs placebo,6 
and empagliflozin treatment was associated with slower progression 
of kidney disease compared with placebo.7 In the Liraglutide Effect 
and	Action	in	Diabetes:	Evaluation	of	Cardiovascular	Outcome	Results	
(LEADER)	 trial	 in	 patients	with	 T2DM	 and	 high	 cardiovascular	 risk,	
treatment	with	the	glucagon-	like	peptide-	1	 (GLP-	1)	receptor	agonist	
liraglutide was associated with a significant reduction in the risk of 
death from cardiovascular causes and a non- significant reduction in 
the	risk	of	non-	fatal	MI,	non-	fatal	stroke	and	hospitalisation	for	heart	
failure compared with placebo.8
Findings from these and other cardiovascular outcome studies 
may, in time, lead to greater use of newer agents (such as SGLT2 in-
hibitors	and	GLP-	1	receptor	agonists)	in	patients	at	high	cardiovascu-
lar risk. Recent European Cardiovascular Society guidelines on CVD 
prevention state that use of an SGLT2 inhibitor should be considered 
early in the course of diabetes management for patients with existing 
CVD based on observed reductions in CVD, total mortality and heart 
failure hospitalisations.9 Use of SGLT2 inhibitors is also supported by 
the growing body of evidence on therapies that can provide multifac-
torial	benefits,	such	as	weight	loss	and	reduced	blood	pressure	(BP),	
in addition to lowering blood glucose.4,10 SGLT2 inhibitors have been 
shown to provide clinically important improvements in glycaemic con-
trol and to induce mild osmotic diuresis, natriuresis and negative en-
ergy	balance,	which	contribute	to	reductions	 in	BP	and	body	weight	
across	 a	 broad	 range	 of	 patients	with	T2DM.11 Recent publications 
suggest that the cardioprotective effects seen with empagliflozin are 
likely to be relevant for the SGLT2 inhibitor class as a whole.12-16
Although	many	of	the	improvements	in	cardiovascular	risk	factors	
have been reported for all SGLT2 inhibitors, this review article focuses 
on describing the effects of canagliflozin on cardiovascular risk fac-
tors based on results from its clinical development programme. Results 
of	 the	 CANagliflozin	 cardioVascular	 Assessment	 Study	 (CANVAS)	
Program17,18 will provide evidence on whether the observed effects 
on cardiovascular risk factors translate into cardiovascular benefits in 
patients	with	T2DM.
2  | EFFECTS OF CANAGLIFLOZIN 
TREATMENT ON CARDIOVASCULAR 
RISK FACTORS
Canagliflozin acts by inhibiting SGLT2, which is the primary media-
tor of renal glucose reabsorption. Such inhibition lowers the renal 
threshold for glucose excretion (RTG),	 which	 increases	 urinary	 glu-
cose	excretion	(UGE)	and	reduces	plasma	glucose	levels	in	an	insulin-	
independent manner.19 Canagliflozin is indicated as an adjunct to diet 
and	exercise	for	the	treatment	of	adults	with	T2DM.11	A	summary	of	
the impact of canagliflozin on cardiovascular risk factors is provided in 
Table 1, along with an overview of the mechanisms that may contrib-
ute to these effects.
2.1 | Glycaemic effects
Chronic hyperglycaemia has been suggested to be a contributor to the 
increased	risk	of	CVD	in	people	with	T2DM,5 and glucose control is 
often considered to be a cornerstone of comprehensive cardiovascular 
risk reduction strategies.20 However, based on findings from studies 
assessing	cardiovascular	risk	in	T2DM,	such	as	ACCORD,	ADVANCE	
and	VADT,	there	is	not	universal	agreement	that	lowering	plasma	glu-
cose levels is a driver for improvements in cardiovascular outcomes. 
These studies evaluated intensive glucose- lowering strategies with 
established therapies and reported negative or neutral effects on car-
diovascular outcomes.21-23	Thus,	the	American	Diabetes	Association	
and	the	European	Association	for	the	Study	of	Diabetes	recommend	
treatment strategies that provide glycaemic control within a multifac-
torial cardiovascular risk reduction framework.20
In a clinical trials programme that enrolled ~10 000 patients with 
T2DM,	including	older	patients,	patients	with	moderate	renal	impair-
ment, and patients with elevated cardiovascular risk, treatment with 
canagliflozin 100 and 300 mg was associated with clinically significant, 
dose-	dependent	 reductions	 in	HbA1c,	 both	 as	monotherapy	 and	 as	
part of combination therapy with metformin ± a sulphonylurea for 
up to 104 weeks.11	In	active-	controlled	Phase	3	studies,	canagliflozin	
300	mg	 provided	 greater	 reductions	 in	HbA1c	 compared	with	 both	
glimepiride and sitagliptin.11
In	addition	to	reducing	HbA1c	levels,	the	increase	in	UGE	that	oc-
curs with canagliflozin treatment is associated with reductions in post-
prandial glucose and insulin excursions.11,19,24-27 Further reductions 
in postprandial glucose also occur through a non- renal mechanism. 
While	data	indicate	that	canagliflozin	does	not	have	systemic	effects	
Review criteria
Structured searches were performed to identify published 
literature related to the effects of the SGLT2 inhibitor cana-
gliflozin on cardiovascular risk factors in patients with 
T2DM.	Articles	 and	 congress	 abstracts	 identified	 in	 these	
searches were evaluated for clinical data on the effects of 
canagliflozin on cardiometabolic outcomes and for informa-
tion about potential mechanisms associated with these 
effects.
Message for the clinic
To reduce the risk of cardiovascular disease in patients with 
T2DM,	treatment	should	focus	on	multifactorial	risk	reduc-
tion.	Published	results	suggest	canagliflozin	may	contribute	
to	improved	cardiometabolic	outcomes	by	lowering	HbA1c,	
body weight and blood pressure; reducing hyperinsulinae-
mia and uric acid levels; and increasing serum magnesium 
levels.	Additional	evidence	on	the	cardiovascular	and	renal	
effects of canagliflozin will be available upon completion of 
large- scale outcomes trials.
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on	SGLT1	(eg,	in	the	kidney,	heart	or	skeletal	muscle),28,29 the 300- mg 
dose may provide transient, local inhibition of SGLT1 in the intestine. 
This intestinal SGLT1 inhibition may slow glucose absorption from 
the morning meal and delay the appearance of glucose in plasma.24 It 
has been hypothesised that such reductions in postprandial hypergly-
caemia and insulin variability may have a greater impact on reducing 
cardiovascular risk than simply reducing average blood glucose levels 
(ie,	HbA1c)	because	processes	that	trigger	oxidative	stress	and	endo-
thelial dysfunction are often upregulated when glucose levels peak or 
fluctuate widely between high and low levels.30
The glycaemic efficacy of canagliflozin is largely independent of 
beta- cell function and insulin sensitivity.31 Thus, it is not surprising 
that canagliflozin has been shown to significantly improve glycae-
mic	control	 in	patients	with	T2DM	across	a	 range	of	ages,	weight/
TABLE  1 Effects of canagliflozin on factors associated with cardiometabolic benefits and risks
Parameter
Effect of 
canagliflozina
Potential SGLT2i- associated mechanisms or 
effects of SGLT2i on factors Predicted effect on CV outcomes
Hyperglycaemia ↓ Urinary glucose excretion
Potential	secondary	effects	based	on	improve-
ments in insulin sensitivity and/or beta- cell 
function
Reduction in chronic hyperglycaemia and glucose 
variability may improve CV outcomes
Plasma	insulin ↓ Decreases in plasma glucose reduce glucose 
stimulation of beta cells
Increased insulin clearance
Reduced hyperinsulinaemia may lower CV risk
Body weight and 
visceral adiposity
↓ Net	caloric	loss	as	a	result	of	urinary	 
glucose excretion
Modest	weight	loss	may	reduce	CVD	risk	in	patients	
with	T2DM
Loss of visceral fat can lower CVD risk by reducing 
inflammation and the potential for atherogenesis
Blood pressure ↓ Osmotic diuresis, natriuresis, reduced intravas-
cular volume, weight loss
Reductions in blood pressure can significantly reduce 
risk of CHD and mortality
Albuminuria ↓ Decreased urinary albumin excretion via 
reduction in GFR through reduction in glucose 
and sodium reabsorption in the proximal tubule
Reduced albuminuria is associated with reduced risk of 
CV and renal disease and associated mortality
May	slow	progression	of	diabetic	nephropathy
Kidney function ↑ Reduced GFR through reduction in glucose and 
sodium reabsorption in the proximal tubule
May	provide	renoprotective	benefits	and	slow	
progression of diabetic nephropathy
LDL- C ↑ Possible	metabolic	effects	of	urinary	glucose	
excretion and haemoconcentration
Abnormalities	in	lipoprotein	metabolism	increase	CV	
risk	in	T2DM
Increasing LDL- C may promote atherogenesis and 
increase risk for development of CVD
HDL- C ↑ Possible	metabolic	effects	of	urinary	glucose	
excretion and haemoconcentration
Associated	with	improvements	in	glycaemic	
control and reduced body weight
Increased	catabolism	of	HDL-	C	in	T2DM	reduces	
cardioprotective effects
SGLT2i	may	modulate	the	impact	of	T2DM	on	HDL-	C	
levels
Triglycerides ↓ Associated	with	improvements	in	glycaemic	
control and reduced body weight
Increased triglyceride level is a primary lipid abnormal-
ity	in	T2DM
Decreases in triglycerides with SGLT2i may reduce risk 
for development of CVD
Uric acid ↓ Increased delivery of glucose to transporters 
that exchange glucose for uric acid
May	reduce	risk	for	nephropathy,	CHD,	and	mortality
Serum magnesium ↑ Consequence of mild osmotic diuresis and 
possibly alterations in renal handling of 
magnesium
May	reverse	magnesium	deficiencies	that	are	
associated with cardiac hypertrophy, aortic stiffening, 
arrhythmias, and rapid declines in renal function
Haemoglobin/
haematocrit
↑ Plasma	volume	contraction	due	to	osmotic	
diuresis; increased haematopoiesis; increases 
in erythropoietin levels
Results are mixed on CV effects of increased 
haemoglobin/haematocrit
Increases	in	the	EMPA-	REG	OUTCOME	study	were	
associated with improvements in HF and mortality 
risk, but may increase risk of thrombotic events
Ketones ↑ Shift in substrate delivery to the heart and 
changes in cardiac insulin sensitivity
Improvements in myocardial and renal fuel metabolism 
may reduce CV risk, but there is also speculation 
about increased risk of thrombotic events
CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; GFR, glomerular filtration rate; HDL- C, high- density lipoprotein cholesterol; 
HF,	heart	failure;	LDL-	C,	low-	density	lipoprotein	cholesterol;	SGLT2i,	sodium	glucose	co-	transporter	2	inhibitors;	T2DM,	type	2	diabetes	mellitus.	aArrows	
indicate the direction of statistically significant changes associated with canagliflozin treatment.
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body	mass	index	categories,	baseline	HbA1c	levels	and	disease	du-
rations.32,33 The risk of hypoglycaemia is generally low with cana-
gliflozin	when	 it	 is	 used	 alone	 or	 in	 combination	with	 other	AHAs	
that have a low intrinsic risk of causing hypoglycaemia.11	A	post	hoc	
analysis	of	data	from	a	Phase	3	study	in	patients	with	T2DM	inad-
equately controlled on metformin showed that a higher proportion 
of	patients	achieved	their	glycaemic	goals	(ie,	HbA1c	<7%	or	<6.5%)	
without hypoglycaemia after 52 weeks of treatment with canagli-
flozin vs the sulphonylurea glimepiride.34	 Notably,	 hypoglycaemia	
may be associated with an increased risk of cardiovascular events. 
The Outcomes Reduction with an Initial Glargine Intervention 
(ORIGIN)	trial	compared	an	insulin	strategy	with	standard	care	using	
oral	AHAs	in	patients	with	early	T2DM	who	were	at	a	high	risk	for	
cardiovascular outcomes. It was observed that patients who expe-
rienced severe hypoglycaemia (ie, requiring assistance or glucose 
≤2.0	mmol/L	 [≤36	mg/dL])	 had	 significantly	 increased	 risks	 for	 the	
composite	of	cardiovascular	death,	non-	fatal	MI	or	stroke,	as	well	as	
all- cause mortality, cardiovascular death and arrhythmic death.35 It 
remains to be seen if the low risk of hypoglycaemia that is associated 
with canagliflozin treatment will also be associated with improved 
cardiovascular outcomes.
2.2 | Effects on insulin secretion/resistance
In	 patients	 with	 T2DM,	 insulin	 resistance	 has	 been	 shown	 to	 de-
velop in target tissues, including liver, adipose, muscle and myocar-
dium. Insulin resistance is a major driver of adverse cardiovascular 
outcomes that acts synergistically with hyperglycaemia to promote 
atherosclerosis.36 Specifically, reduced insulin signalling in endothe-
lial tissue is associated with increased vascular dysfunction, inflam-
mation, oxidative stress and the development of atherosclerotic 
lesions.36
Analysis	 of	 data	 from	 three	 Phase	 3	 studies	 of	 canagliflozin	
as monotherapy and as add- on to metformin plus sulphonylurea 
showed that 6- 12 months of canagliflozin treatment improves both 
fasting and postprandial measures of beta- cell function and insulin 
secretion.37 Insulin secretion rate was significantly increased with 
canagliflozin compared with baseline at all plasma glucose concen-
trations	(7-	16	mmol/L);	these	increases	were	of	similar	magnitude	
with canagliflozin vs sitagliptin.37 Insulin sensitivity, measured 
using the oral glucose insulin sensitivity index corrected for UGE, 
also improved by approximately 15% with canagliflozin treat-
ment.37 It has been hypothesised that such improvements in insulin 
sensitivity are a result of weight loss and the reversal of glucotoxic-
ity. Improvement in hyperinsulinaemia may reduce the risk of ath-
erosclerosis beyond that of glucose lowering alone.5,38 In a rodent 
model,	Watanabe	and	colleagues	showed	that	the	combination	of	
canagliflozin with pioglitazone reduced hyperinsulinaemia and im-
proved whole- body insulin sensitivity compared with pioglitazone 
monotherapy.39 Further studies are needed to confirm whether in-
direct improvement in insulin sensitivity of the magnitude observed 
in studies of canagliflozin has a significant effect on atherosclerosis 
risk	in	people	with	T2DM.5
2.3 | Effects on body weight and adiposity
Modest	weight	 loss	of	between	5%	and	10%	can	contribute	 to	 im-
provements in glycaemic control and may reduce CVD risk factors in 
overweight	 and	 obese	 patients	with	 T2DM.40	While	 overall	 results	
from	 the	 Look	AHEAD	 study	 in	 overweight	 or	 obese	 patients	with	
T2DM	did	not	find	an	association	between	intensive	lifestyle	interven-
tion promoting weight loss and a reduced rate of adverse cardiovas-
cular events,41 a recent post hoc analysis of risk based on magnitude 
of weight loss showed that patients who lost more than 10% of their 
body weight had a 20% reduction in risk of the composite of cardio-
vascular	death,	non-	fatal	acute	MI,	non-	fatal	stroke	or	hospitalisation	
for angina42; prospective studies are needed to further examine the 
effects of weight loss on cardiovascular outcomes.
Across	 Phase	 3	 studies,	 canagliflozin	 100	 and	 300	mg	 have	
been associated with dose- dependent reductions in body weight.11 
Generally, average body weight reductions observed with canagliflozin 
treatment were between 2% and 5%,11 and more patients achieved 
a weight loss of at least 5% or 10% with canagliflozin than with pla-
cebo or active comparators.43,44 This weight loss was sustained over 
104 weeks of treatment in clinical trials.44-46
Weight	 loss	 associated	 with	 canagliflozin	 and	 other	 SGLT2	 in-
hibitors is a result of reductions in both visceral and subcutaneous 
adipose tissue.47-50	Body	composition	measurements	from	a	Phase	3	
study	of	canagliflozin	in	patients	with	T2DM	inadequately	controlled	
on metformin showed a mean change in visceral adipose tissue of 
−7.3%	with	 canagliflozin	 100	mg,	 −8.1%	with	 canagliflozin	 300	mg,	
and 0.1% with glimepiride at 52 weeks; change in subcutaneous adi-
pose	tissue	was	−5.4%	with	canagliflozin	100	mg,	−5.6%	with	canagli-
flozin 300 mg and 1.8% with glimepiride.50 The loss of visceral fat with 
canagliflozin treatment is noteworthy because visceral fat mass has 
been	shown	to	increase	cardiometabolic	risk	in	patients	with	T2DM	
by promoting atherogenic, thrombotic and inflammatory abnormali-
ties.47 In addition, visceral adiposity has been associated with concen-
tric left ventricle remodelling, reduced cardiac output and increased 
systemic vascular resistance.51 Thus, the weight- related benefits as-
sociated with canagliflozin treatment are enhanced by reductions in 
visceral adiposity that may reduce cardiovascular complications and 
mortality.5
2.4 | Effects on blood pressure, pulse pressure and 
arterial stiffness
BP	control	is	critical	in	patients	with	T2DM.	The	combination	of	T2DM	
and hypertension increases the risk of coronary heart disease and as-
sociated	mortality	dramatically	(up	to	six-	fold)	compared	with	either	
disease alone.52 Elevated pulse pressure (ie, the difference between 
systolic	and	diastolic	BP)	and	mean	arterial	pressure	(ie,	the	average	
pressure	during	a	single	cardiac	cycle	[2/3	diastolic	BP	+	1/3	systolic	
BP])	also	significantly	increase	CVD	risk	in	patients	with	T2DM.53 In a 
meta- analysis of CVD risk related to pulse pressure and mean arterial 
pressure, each 10- mmHg incremental increase in pressure was associ-
ated with about a 10% increase in risk for CVD.53
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Across	clinical	studies,	canagliflozin	treatment	has	been	shown	to	
provide	significant	reductions	 in	BP.	Pooled	data	from	four	placebo-	
controlled	 studies	 showed	mean	 systolic	BP	 reductions	of	−4.3	and	
−5.0	mmHg	 with	 canagliflozin	 100	 and	 300	mg,	 respectively,	 vs	
−0.3	mmHg	with	placebo.54 In these studies, greater proportions of 
patients	achieved	systolic	BP	targets	of	<140	and	<130	mm	Hg	with	
canagliflozin vs placebo.54	 The	 BP-	lowering	 effects	 of	 canagliflozin	
are not significantly altered when patients are taking antihypertensive 
medications	or	other	AHAs,	and	BP	reduction	with	canagliflozin	is	not	
associated with meaningful changes in heart rate.54	 In	 addition,	 BP	
reductions with canagliflozin in patients with moderate renal impair-
ment	 (estimated	 glomerular	 filtration	 rate	 [eGFR]	 ≥30	 and	 <50	mL/
min/1.73 m2)	are	comparable	 to	 those	 in	patients	with	normal	 renal	
function,	 despite	 differences	 in	 UGE	 and	 HbA1c	 efficacy	 observed	
with canagliflozin in these patient populations.55,56
Pooled	 data	 from	 four	 placebo-	controlled	 studies	 showed	 that	
canagliflozin treatment was associated with reductions in pulse pres-
sure, mean arterial pressure and double product (ie, heart rate × sys-
tolic	BP)	compared	with	placebo.57 Similar results were observed in a 
6-	week	ambulatory	BP	monitoring	study	in	patients	with	T2DM	and	
hypertension;	 BP	 reductions	with	 canagliflozin	 occurred	 quickly,	 as	
early as 2 days after initiation of therapy.58	These	rapid	effects	on	BP	
are likely due to osmotic diuresis, natriuresis and reduced intravascular 
volume.57,58	Long-	term	reductions	 in	BP	are	 likely	a	result	of	weight	
loss and changes in the renin- angiotensin system.58 Empagliflozin 
has been shown to reduce arterial stiffness in patients with type 1 
diabetes mellitus, and it has been speculated that SGLT2 inhibitors 
may improve endothelial function or the elastic properties of various 
components of connective tissue.5 SGLT2 inhibitors may also reduce 
intracardiac filling pressure, which may reduce myocardial stretch and 
reduce the risk of ventricular arrhythmia.59
2.5 | Renal effects
Albuminuria	 is	a	well-	established	marker	 for	CVD	and	renal	disease	
in	patients	with	T2DM,	significantly	increasing	risk	of	cardiovascular	
death.60,61 SGLT2 inhibition has been shown to decrease urinary al-
bumin	excretion	by	reducing	glomerular	filtration	rate	(GFR)	through	
reduction in glucose and sodium reabsorption in the proximal tubule, 
which increases sodium delivery to the macula densa in the distal 
tubule and suppresses activation of tubuloglomerular feedback.62-64 
As	an	added	benefit,	reductions	 in	GFR	during	sympathetic	nervous	
system activation that result from reduced glycaemia and increased 
hepatic gluconeogenesis may act to stabilise glucose perturbations.5
Across	 Phase	 3	 studies	 of	 canagliflozin,	 early	 transient	 reduc-
tions in eGFR were observed regardless of baseline renal function.65 
Changes in eGFR generally attenuated to near baseline levels and 
stabilised over time for all patients, including those with chronic kid-
ney	disease	(CKD).56,66 In studies of patients with CKD, decreases in 
median	albumin-	to-	creatinine	ratio	 (ACR)	were	also	observed,	which	
were likely a result of volume contraction.56,66	 A	 post	 hoc	 analysis	
of	results	from	a	Phase	3	study	in	patients	with	T2DM	inadequately	
controlled on metformin showed that canagliflozin treatment slowed 
the	progressive	decline	in	eGFR	and	lowered	the	ACR	compared	with	
glimepiride.67	The	ongoing	CANagliflozin	 cardioVascular	Assessment	
Study–Renal	(CANVAS-	R;	NCT01989754)	and	Canagliflozin	and	Renal	
Events	in	Diabetes	with	Established	Nephropathy	Clinical	Evaluation	
(CREDENCE;	NCT02065791)	studies	will	provide	additional	data	on	
the effects of canagliflozin on renal- related outcomes.18,68
2.6 | Effects on lipids
Dyslipidaemia plays a critical role in the development of CVD, espe-
cially	 in	patients	with	T2DM,9 and lipid profile management has be-
come	an	important	component	of	multifactorial	T2DM	management.5 
Canagliflozin has been shown to have beneficial effects on high- 
density	 lipoprotein	cholesterol	 (HDL-	C)	and	triglyceride	 levels,	 likely	
as a result of improvements in glycaemic control and reductions in 
body weight.69 In pooled placebo- controlled studies, mean placebo- 
subtracted increases in HDL- C were 5.4% and 6.3%, respectively, 
with	canagliflozin	100	and	300	mg	at	Week	26,	and	mean	placebo-	
subtracted	 reductions	 in	 triglyceride	 levels	were	 −5.2%	 and	 −7.6%,	
respectively.69
Canagliflozin has also been shown to increase low- density lipo-
protein	cholesterol	(LDL-	C)	and	total	cholesterol	relative	to	placebo.69 
Across	 four	 pooled	 placebo-	controlled	 studies,	 mean	 placebo-	
subtracted increases in LDL- C were 4.5% and 8.0%, respectively, with 
canagliflozin	100	and	300	mg	at	Week	26.69 In a pooled analysis of 
two active- controlled studies, the percentage of patients with LDL- C 
levels	≥100	mg/dL	was	not	increased	from	baseline	to	Week	52	with	
canagliflozin	treatment	and	was	not	different	at	Week	52	with	canagli-
flozin vs sitagliptin.70	In	contrast	to	results	in	patients	with	T2DM	who	
have normal or mild renal impairment, reductions in LDL- C have been 
seen with canagliflozin in patients with moderate renal impairment 
over	52	weeks	 (placebo-	subtracted	differences	of	−3.0%	and	−6.9%	
with	canagliflozin	100	and	300	mg,	respectively).56 The mechanism for 
the observed changes in LDL- C with SGLT2 inhibition is not fully un-
derstood, but it has been hypothesised that these changes are related 
to downstream metabolic effects of UGE and haemoconcentration.71
2.7 | Effects on uric acid
Hyperuricaemia	in	patients	with	T2DM	is	associated	with	an	increased	
risk of gout, nephropathy, coronary heart disease and mortality.72,73 In 
a meta- analysis of studies that included more than 20 000 patients 
with	T2DM,	Xu	 and	 colleagues	 found	 that	 for	 each	100	μmol/L in-
crease	in	serum	uric	acid,	patients	with	T2DM	experienced	a	28%	in-
crease in the risk of vascular complications (eg, stroke, coronary heart 
disease,	 peripheral	 vascular	 disease	 and	nephropathy)	 and	 a	9%	 in-
crease in risk of mortality.73
Several studies have examined the effects of SGLT2 inhibitors on 
uric	acid	levels	in	patients	with	T2DM.62,74-76	In	Phase	1	studies	eval-
uating the pharmacodynamic effects of canagliflozin in patients with 
T2DM,	fractional	urinary	excretion	of	uric	acid	was	increased	during	the	
first weeks of treatment with canagliflozin, resulting in a small decrease 
(~0.1	pH	units)	in	mean	urine	pH	and	up	to	a	20%	reduction	in	serum	
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uric	 acid	 levels	 from	 baseline	 to	Week	 16.27,77 These findings were 
confirmed based on pooled data from four placebo- controlled studies, 
which showed that patients treated with canagliflozin for 26 weeks 
had	a	mean	reduction	 in	serum	uric	acid	of	~13%	(~0.7	mg/dL)	com-
pared with placebo.74 In the subset of patients with hyperuricaemia 
at baseline, higher percentages of patients achieved normal uric acid 
levels	(<360	μmol/L	[~6	mg/dL])	with	canagliflozin	100	mg	(23.5%)	and	
	canagliflozin	300	mg	(32.4%)	than	with	placebo	(3.1%).74 The mecha-
nism by which canagliflozin promotes excretion of uric acid is not well 
understood, but it has been speculated that SGLT2 inhibition modulates 
the actions of solute carrier family 2, facilitated glucose transporter 
member	9	(SLC2A9;	also	called	GLUT9),	which	exchanges	glucose	for	
uric acid.78,79
2.8 | Effects on magnesium
Hypomagnesaemia	 (serum	magnesium	<0.74	mmol/L	[1.8	mg/dL])	 is	
associated	with	rapid	progression	of	T2DM	and	may	increase	risks	for	
cardiometabolic complications.80-84 Specifically, magnesium deficien-
cies have been linked with cardiac hypertrophy, aortic stiffening, ar-
rhythmias	(especially	atrial	fibrillation	and	ventricular	tachycardia)	and	
rapid	declines	in	renal	function	in	patients	with	T2DM.	Magnesium	is	
necessary for regulation of ion channels in pancreatic beta cells and 
for	autophosphorylation	of	insulin	receptors.	As	such,	magnesium	de-
ficiency is strongly associated with declines in beta- cell function and 
the development of insulin resistance.80-84
In a meta- analysis of randomised controlled trials of SGLT2 inhib-
itors	in	patients	with	T2DM,	Tang	and	colleagues	found	that	all	evalu-
ated	drugs	(canagliflozin,	dapagliflozin,	empagliflozin	and	ipragliflozin)	
were associated with modest increases in serum magnesium levels 
ranging from 0.05 to 0.10 mmol/L.85 Changes in magnesium levels 
were similar in patients with normal renal function and with CKD.85
In a pooled analysis of data from four placebo- controlled studies, 
canagliflozin was associated with increased serum magnesium levels 
compared with placebo after 26 weeks of treatment (mean percent 
changes	of	8.1%,	9.3%	and	−0.6%	with	canagliflozin	100	and	300	mg	
and	placebo,	respectively).69	Patients	with	hypomagnesaemia	(serum	
magnesium	 <0.74	mmol/L)	 at	 baseline	 were	 more	 likely	 to	 achieve	
serum	magnesium	≥0.74	mmol/L	(ie,	normal	levels)	at	Week	26	with	
canagliflozin than placebo.86 The mechanism for increased serum 
magnesium with canagliflozin has not been established, but may be 
related to improvements in insulin sensitivity37 or changes in the distal 
convoluted tubule that alter magnesium reabsorption and/or urinary 
magnesium excretion.87,88 It remains to be shown whether normalisa-
tion	of	serum	magnesium	with	SGLT2	inhibitors	in	patients	with	T2DM	
will affect disease progression or cardiometabolic outcomes.
2.9 | Effects on haemoglobin/haematocrit
The relationship between increases in haemoglobin/haematocrit and 
the risk of CVD is not well defined, with some studies showing varia-
tions in risk based on age, gender and type of cardiovascular event.89 
Recent data from the Framingham Heart Study showed that higher 
haematocrit levels were associated with an increased risk of develop-
ment of heart failure, even when levels were within normal ranges.90
In a pooled analysis of data from four placebo- controlled studies, 
both doses of canagliflozin were associated with increases in hae-
moglobin compared with placebo.69	At	Week	 26,	 the	 proportion	 of	
patients	with	increases	in	haemoglobin	of	≥20	g/L	from	baseline	was	
6.0% with canagliflozin 100 mg, 5.5% with canagliflozin 300 mg and 
1.0%	with	placebo.	 Increases	 in	haematocrit	 from	baseline	 to	Week	
26 were 5.8% and 6.3% with canagliflozin 100 and 300 mg, respec-
tively, compared with 0.2% in the placebo group.69	In	the	EMPA-	REG	
OUTCOME	study,	the	observed	modest	increases	in	haematocrit	and	
haemoglobin levels were strongly associated with improvements in 
heart failure and mortality risk, suggesting that SGLT2 inhibition may 
affect	mechanisms	other	than	(or	in	addition	to)	plasma	volume	con-
traction to increase haemoglobin levels and thereby oxygen delivery 
to ischaemic tissues.59
2.10 | Effects on ketone bodies
The heart readily consumes ketone bodies and, by some measures, 
these are a preferred cardiac substrate.91,92 Together with changes in 
other substrate delivery to the heart and potential changes in cardiac 
insulin sensitivity, increased levels of circulating ketone bodies seen 
with SGLT2 inhibition might lead to improvements in cardiac metabo-
lism. Elevations in ketone bodies seen with SGLT2 inhibitors have been 
highly variable, with most of the data obtained from small, short- term 
studies.	Results	from	several	Phase	3	studies	in	Japanese	patients	with	
T2DM	have	shown	that,	on	average,	canagliflozin	treatment	is	associ-
ated with a roughly two-fold elevation in plasma ketone bodies.93-96
2.11 | Safety considerations
Overall, canagliflozin has been shown to be generally well tolerated 
as	 monotherapy	 and	 as	 part	 of	 combination	 therapy	 for	 T2DM.69 
Across	four	26-	week,	placebo-	controlled	studies,	the	total	incidence	
of	adverse	events	(AEs)	was	similar	with	canagliflozin	100	and	300	mg	
and placebo.69 Subsequent analysis of data from seven placebo- and 
active- controlled studies confirmed the favourable safety profile of 
canagliflozin for up to 104 weeks.97 Throughout the clinical develop-
ment	programme,	AEs	that	occurred	at	a	higher	rate	with	canagliflo-
zin	vs	placebo	and	other	AHA	comparators	included	genital	mycotic	
infections	and	osmotic	diuresis–	related	AEs,	which	are	related	to	the	
mechanism of SGLT2 inhibition.11	A	modest	increase	in	urinary	tract	
infections	(UTIs)	was	seen	with	canagliflozin	100	and	300	mg	vs	pla-
cebo in the pooled placebo- controlled dataset, but there was no in-
crease in the incidence of serious UTIs with canagliflozin.69,98
Due to the reduced efficacy of canagliflozin in patients with renal 
impairment and the need for more safety data in this population, 
 canagliflozin is not recommended in patients with an eGFR below 
45 mL/min/1.73 m2.19,65	As	noted	 for	 some	antihypertensive	agents	
such	as	angiotensin-	converting	enzyme	(ACE)	inhibitors	and	angioten-
sin	 II	 receptor	blockers	 (ARBs),	and	for	AHAs	 including	some	dipep-
tidyl	peptidase-	4	 inhibitors	and	GLP-	1	receptor	agonists,	 there	have	
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been postmarketing reports of acute kidney injury with SGLT2 inhib-
itors.99-102 However, it is important to note that renal impairment is 
very	common	in	patients	with	T2DM	and	that	T2DM	is	the	most	com-
mon cause of kidney failure in most developed countries.103,104 Other 
risk factors for acute kidney injury include hypovolaemia, chronic renal 
insufficiency,	congestive	heart	failure,	and	concomitant	use	of	ACE	in-
hibitors,	ARBs	or	nonsteroidal	anti-	inflammatory	drugs.99
Possible	adverse	effects	of	SGLT2	inhibitors	on	bone	health	have	
been	 reported.	Across	Phase	3	 studies,	 canagliflozin	was	associated	
with an increased incidence of fractures that generally occurred early 
after treatment initiation.105	 Most	 of	 the	 observed	 fractures	 were	
located in distal parts of the upper and lower extremities and not 
in typical osteoporotic regions, such as the hips and spine.105 Thus, 
these excess fractures may be due, at least in part, to falls induced by 
early	 fluid	 shifts	 (ie,	 transient	hypovolaemia)	 and	not	 a	direct	effect	
on bone density. The observed increase in fractures with canagliflozin 
was	driven	by	 interim	results	from	CANVAS,	 in	which	patients	were	
older, had a history/high risk of CVD, had a lower baseline eGFR, and 
reported higher use of loop diuretics. Similar types of fracture (ie, 
upper	 extremity)	 observations	 have	 been	made	 in	 studies	with	 em-
pagliflozin106 and dapagliflozin101	in	high-	risk	individuals	with	T2DM,	
suggesting that an increased risk of fractures may be a class effect for 
all SGLT2 inhibitors.
It has been suggested that the observed mild hyperketonaemia 
and haemoconcentration associated with SGLT2 inhibition may in-
crease the risk for thrombotic events.12 This may explain the numer-
ically higher incidence of stroke seen with empagliflozin vs placebo 
(3.5%	 vs	 3.0%;	 hazard	 ratio	 [95%	 confidence	 interval],	 1.18	 [0.98-	
1.56])	 in	 the	 EMPA-	REG	 OUTCOME	 study.6	 Another	 thrombotic	
safety signal was raised that is related to peripheral limb ischaemia 
based	on	interim	results	from	CANVAS,	which	showed	higher	rates	of	
amputations	 (mostly	toes)	with	canagliflozin	100	mg	(seven	of	every	
1000	patients)	and	canagliflozin	300	mg	(five	of	every	1000	patients)	
vs	placebo	 (three	of	every	1000	patients).107 However, it should be 
noted	that	the	patient	inclusion	and	exclusion	criteria	for	CANVAS	al-
lowed for enrolment of patients with peripheral arterial disease, which 
may have affected levels of baseline risk for peripheral limb ischaemia. 
Furthermore, a higher incidence of amputation was not observed 
across	 the	 12	 other	 completed	 Phase	 3	 and	 Phase	 4	 clinical	 trials,	
which had a mean follow- up time of 0.9 years (0.6 amputations per 
1000 patient- years with canagliflozin vs two amputations per 1000 
patient-	years	with	placebo/comparator).97 Upon completion of the tri-
als	 in	the	CANVAS	Program	(ie,	CANVAS17	and	CANVAS-	R18),	more	
comprehensive, long- term safety assessments will be possible using 
the final study results.
Concerns about an increased risk of diabetic ketoacidosis have 
been reported with all marketed SGLT2 inhibitors. The overall inci-
dence	of	serious	AEs	of	diabetic	ketoacidosis	was	generally	low	across	
randomised	 controlled	 trials	 of	 canagliflozin	 (4/5337	 [0.07%]	 with	
canagliflozin	100	mg,	6/5350	[0.11%]	with	canagliflozin	300	mg,	and	
2/6909	[0.03%]	with	comparators)	and	consistent	with	the	observed	
rate of diabetic ketoacidosis in the general population of patients with 
T2DM	and	in	patients	treated	with	other	SGLT2	inhibitors.108,109
3  | CONCLUSIONS
Cardiovascular complications are the cause of many adverse outcomes 
associated	with	T2DM.	Given	the	high	burden	of	CVD	in	T2DM,	mul-
tifactorial risk reduction is an important goal, with treatment strate-
gies focusing on improving glycaemic control, as well as weight loss, 
BP	reduction	and	improvements	in	dyslipidaemia.
The	EMPA-	REG	OUTCOME	study	showed	that	empagliflozin	may	
provide cardiometabolic benefits that can lead to a reduction in cardio-
vascular	and	all-	cause	mortality	in	patients	with	T2DM	and	established	
CVD.	Of	note,	the	US	Food	and	Drug	Administration	recently	approved	
a new indication for empagliflozin to reduce the risk of cardiovascular 
death	in	adult	patients	with	T2DM	and	CVD	based	on	results	from	the	
EMPA-	REG	OUTCOME	trial.102 Given the similarities in clinical effects 
of SGLT2 inhibitors on cardiovascular risk factors,110 it is possible that 
these benefits will extend to other drugs in this class.111 Results from 
the canagliflozin clinical development programme support that cana-
gliflozin treatment may improve cardiometabolic outcomes in a broad 
range of patients with diverse clinical characteristics. The potential ben-
efit of this class of agents on persons at risk for congestive heart failure 
may	be	particularly	 important,	 given	 the	benefits	 seen	 in	 the	EMPA-	
REG	OUTCOME	trial112 and the observed effects of SGLT2 inhibitors 
on	BP,	volume	status	and	intracardiac	filling	pressures.54,113	Additional	
data on the cardiovascular and renal effects of canagliflozin in patients 
with a history or high risk of cardiovascular events will be available upon 
completion	of	the	large-	scale	CANVAS	Program	in	2017.17,18,114
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